Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin
- 8 January 1987
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 316 (2) , 73-78
- https://doi.org/10.1056/nejm198701083160203
Abstract
We administered recombinant human erythropoietin to 25 anemic patients with end-stage renal disease who were undergoing hemodialysis. The recombinant human erythropoietin was given intravenously three times weekly after dialysis, and transfusion requirements, hematocrit, ferrokinetics, and reticulocyte responses were monitored.This publication has 18 references indexed in Scilit:
- Isolation and characterization of genomic and cDNA clones of human erythropoietinNature, 1985
- Identification of Spermine as an Inhibitor of Erythropoiesis in Patients with Chronic Renal FailureJournal of Clinical Investigation, 1981
- Effect of parathyroid hormone on erythropoiesis.Journal of Clinical Investigation, 1981
- A Comparison of Androgens for Anemia in Patients on HemodialysisNew England Journal of Medicine, 1981
- Effect of erythropoietin on anemia of peritoneally dialyzed anephric ratsKidney International, 1979
- Effect of Erythropoietin Therapy on the Red Cell Volume of Uraemic and Non-uraemic RatsBritish Journal of Haematology, 1977
- Hemodynamics of Uremic AnemiaCirculation, 1972
- Hypersplenism in the Uremic Hemodialyzed PatientNephron, 1972
- Hemodynamics of Uremic AnemiaCirculation, 1971
- FERROKINETICS IN MANMedicine, 1970